Author
Lorenzo Menicanti
Other affiliations: University of California, Los Angeles, University of Florence
Bio: Lorenzo Menicanti is an academic researcher from University of Milan. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 46, co-authored 211 publications receiving 9275 citations. Previous affiliations of Lorenzo Menicanti include University of California, Los Angeles & University of Florence.
Papers published on a yearly basis
Papers
More filters
TL;DR: Guidelines and Expert Consensus Documents summarize and evaluate all available evidence with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome and the risk benefit ratio of diagnostic or therapeutic means.
Abstract: Guidelines and Expert Consensus Documents summarize and
evaluate all available evidence with the aim of assisting
physicians in selecting the best management strategy for an
individual patient suffering from a given condition, taking
into account the impact on outcome and the risk benefit
ratio of diagnostic or therapeutic means. Guidelines are no
substitutes for textbooks and their legal implications have
been discussed previously. Guidelines and recommendations should help physicians to make decisions in their daily
practice. However, the ultimate judgement regarding the
care of an individual patient must be made by his/her
responsible physician(s).
The recommendations for formulating and issuing ESC
Guidelines and Expert Consensus Documents can be found
on the ESC website (http://www.escardio.org/knowledge/
guidelines/rules).
Members of this Task Force were selected by the European
Society of Cardiology (ESC) and the European Association for
Cardio-Thoracic Surgery (EACTS) to represent all physicians
involved with the medical and surgical care of patients
with coronary artery disease (CAD). A critical evaluation
of diagnostic and therapeutic procedures is performed
including assessment of the risk benefit ratio. Estimates
of expected health outcomes for society are included,
where data exist. The level of evidence and the strength
of recommendation of particular treatment options are
weighed and graded according to predefined scales, as
outlined in Tables 1 and 2.
The members of the Task Force have provided disclosure
statements of all relationships that might be perceived as
real or potential sources of conflicts of interest. These
disclosure forms are kept on file at European Heart House,
headquarters of the ESC. Any changes in conflict of interest
that arose during the writing period were notified to the ESC.
The Task Force report received its entire financial support
from the ESC and EACTS, without any involvement of the
pharmaceutical, device, or surgical industry.
ESC and EACTS Committees for Practice Guidelines are
responsible for the endorsement process of these joint
Guidelines. The finalized document has been approved by all
the experts involved in the Task Force, and was submitted to
outside specialists selected by both societies for review. The
document is revised, and finally approved by ESC and EACTS and subsequently published simultaneously in the European
Heart Journal and the European Journal of Cardio-Thoracic
Surgery.
After publication, dissemination of the Guidelines is of
paramount importance. Pocket-sized versions and personal
digital assistant-downloadable versions are useful at the
point of care.
Some surveys have shown that the intended users are
sometimes unaware of the existence of guidelines, or simply
do not translate them into practice. Thus, implementation
programmes are needed because it has been shown that
the outcome of disease may be favourably influenced by the
thorough application of clinical recommendations.
1,544 citations
TL;DR: Few observations exist with respect to the pro‐coagulant profile of patients with COVID‐19 acute respiratory distress syndrome and reports of thromboembolic complications are scarce but suggestive for a clinical relevance of the problem.
757 citations
TL;DR: Adding surgical ventricular reconstruction to CABG reduced the left ventricular volume, as compared with CABGs alone, however, this anatomical change was not associated with a greater improvement in symptoms or exercise tolerance or with a reduction in the rate of death or hospitalization for cardiac causes.
Abstract: Background Surgical ventricular reconstruction is a specific procedure designed to reduce left ventricular volume in patients with heart failure caused by coronary artery disease. We conducted a trial to address the question of whether surgical ventricular reconstruction added to coronary-artery bypass grafting (CABG) would decrease the rate of death or hospitalization for cardiac causes, as compared with CABG alone. Methods Between September 2002 and January 2006, a total of 1000 patients with an ejection fraction of 35% or less, coronary artery disease that was amenable to CABG, and dominant anterior left ventricular dysfunction that was amenable to surgical ventricular reconstruction were randomly assigned to undergo either CABG alone (499 patients) or CABG with surgical ventricular reconstruction (501 patients). The primary outcome was a composite of death from any cause and hospitalization for cardiac causes. The median follow-up was 48 months. Results Surgical ventricular reconstruction reduced the end-systolic volume index by 19%, as compared with a reduction of 6% with CABG alone. Cardiac symptoms and exercise tolerance improved from baseline to a similar degree in the two study groups. However, no significant difference was observed in the primary outcome, which occurred in 292 patients (59%) who were assigned to undergo CABG alone and in 289 patients (58%) who were assigned to undergo CABG with surgical ventricular reconstruction (hazard ratio for the combined approach, 0.99; 95% confidence interval, 0.84 to 1.17; P = 0.90). Conclusions Adding surgical ventricular reconstruction to CABG reduced the left ventricular volume, as compared with CABG alone. However, this anatomical change was not associated with a greater improvement in symptoms or exercise tolerance or with a reduction in the rate of death or hospitalization for cardiac causes. (ClinicalTrials. gov number, NCT00023595.)
656 citations
TL;DR: The International Registry of Acute Aortic Dissection experience confirms that patient selection plays an important role in determining surgical outcomes in patients with acute type A aortic dissection and knowledge of significant risk factors for operative mortality can contribute to better management and a more defined risk assessment in patients affected by acute type C aorta dissection.
514 citations
TL;DR: Surgical ventricular restoration improves ventricular function and is highly effective therapy in the treatment of ischemic cardiomyopathy with excellent five-year outcome.
434 citations
Cited by
More filters
TL;DR: Authors/Task Force Members: Piotr Ponikowski* (Chairperson) (Poland), Adriaan A. Voors* (Co-Chair person) (The Netherlands), Stefan D. Anker (Germany), Héctor Bueno (Spain), John G. F. Cleland (UK), Andrew J. S. Coats (UK)
13,400 citations
TL;DR: In this article, Anderson et al. proposed a new FAHA Chair, Jeffrey L. Anderson, MD, FACC, FAHA, Chair-Elect, Alice K. Jacobs et al., this article and Biykem Bozkurt.
11,386 citations
TL;DR: ACCF/AHAIAI: angiotensin-converting enzyme inhibitor as discussed by the authors, angio-catabolizing enzyme inhibitor inhibitor inhibitor (ACS inhibitor) is a drug that is used to prevent atrial fibrillation.
Abstract: ACC/AHA
: American College of Cardiology/American Heart Association
ACCF/AHA
: American College of Cardiology Foundation/American Heart Association
ACE
: angiotensin-converting enzyme
ACEI
: angiotensin-converting enzyme inhibitor
ACS
: acute coronary syndrome
AF
: atrial fibrillation
7,489 citations
TL;DR: Authors/Task Force Members: Piotr Ponikowski* (Chairperson) (Poland), Adriaan A. Voors* (Co-Chair person) (The Netherlands), Stefan D. Anker (Germany), Héctor Bueno (Spain), John G. F. Cleland (UK), Andrew J. S. Coats (UK)
Abstract: ACC/AHA
: American College of Cardiology/American Heart Association
ACCF/AHA
: American College of Cardiology Foundation/American Heart Association
ACE
: angiotensin-converting enzyme
ACEI
: angiotensin-converting enzyme inhibitor
ACS
: acute coronary syndrome
AF
: atrial fibrillation
6,757 citations
TL;DR: Authors/Task Force Members: John J. McMurray (Chairperson) (UK), Stamatis Adamopoulos (Greece), Stefan D. Anker (Germany), Angelo Auricchio (Switzerland), Michael Böhm ( Germany), Kenneth Dickstein (Norway), Volkmar Falk (Sw Switzerland), Gerasimos Filippatos (G Greece), Cândida Fonseca (Portugal), Miguel Angel Gomez-Sanchez (Spain).
Abstract: Authors/Task Force Members: John J.V. McMurray (Chairperson) (UK)*, Stamatis Adamopoulos (Greece), Stefan D. Anker (Germany), Angelo Auricchio (Switzerland), Michael Böhm (Germany), Kenneth Dickstein (Norway), Volkmar Falk (Switzerland), Gerasimos Filippatos (Greece), Cândida Fonseca (Portugal), Miguel Angel Gomez-Sanchez (Spain), Tiny Jaarsma (Sweden), Lars Køber (Denmark), Gregory Y.H. Lip (UK), Aldo Pietro Maggioni (Italy), Alexander Parkhomenko (Ukraine), Burkert M. Pieske (Austria), Bogdan A. Popescu (Romania), Per K. Rønnevik (Norway), Frans H. Rutten (The Netherlands), Juerg Schwitter (Switzerland), Petar Seferovic (Serbia), Janina Stepinska (Poland), Pedro T. Trindade (Switzerland), Adriaan A. Voors (The Netherlands), Faiez Zannad (France), Andreas Zeiher (Germany).
6,367 citations